Alto Neuroscience Receives FDA Fast Track Designation for Drug Candidate ALTO-101 for Cognitive Impairment in Schizophrenia

Alto Neuroscience Inc. (NYSE:ANRO) is one of the best young stocks with huge upside potential. On October 3, Alto ...
TipRanks on MSN

Alto Neuroscience price target raised to $16 from $10 at Baird

Baird raised the firm’s price target on Alto Neuroscience (ANRO) to $16 from $10 and keeps an Outperform rating on the shares after Alto announced ...
Stocktwits on MSN

Alto Neuroscience Stock Soars After FDA Grants Fast Track Designation To Schizophrenia Drug

Shares of Alto Neuroscience (ANRO) soared 54% on Friday afternoon after the company announced that the U.S. Food and Drug Administration granted Fast Track designation to ALTO-101 for the treatment of ...
Investing.com South Africa

Alto Neuroscience stock soars after FDA meeting clears path for depression drug

Investing.com -- Alto Neuroscience Inc (NYSE:ANRO) stock surged 81% Monday after the company announced a successful FDA meeting that will accelerate development of its treatment-resistant depression ...
Business Wire

Trace Neuroscience Launches With $101 Million Series A Financing to Expand Genomic Medicine for Neurodegenerative Diseases

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Trace Neuroscience, Inc., a biopharmaceutical company expanding the promise of genomic medicine for people living with neurodegenerative diseases, today ...
Yahoo Finance

Alto Neuroscience Receives FDA Fast Track Designation for ALTO-101 for the Treatment of Cognitive Impairment Associated with Schizophrenia

– Enrollment remains ongoing in a Phase 2 proof-of-concept study of ALTO-101 in patients with CIAS – MOUNTAIN VIEW, Calif., October 03, 2025--(BUSINESS WIRE)--Alto Neuroscience, Inc. ("Alto") (NYSE: ...

Alto Neuroscience stock soars after FDA grants Fast Track designation

Investing.com -- Alto Neuroscience Inc (NYSE:ANRO) stock surged 32.3% Friday after the company announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its drug ...
Business Wire

Alto Neuroscience Receives FDA Fast Track Designation for ALTO-101 for the Treatment of Cognitive Impairment Associated with Schizophrenia

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for ...
Morningstar

Alto Neuroscience Receives FDA Fast Track Designation for ALTO-101 for the Treatment of Cognitive Impairment Associated with Schizophrenia

– Enrollment remains ongoing in a Phase 2 proof-of-concept study of ALTO-101 in patients with CIAS – Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on ...